Case Studies: Deployer

Dermathology Portfolio Expansion

through an innovative

topical therapy

Introduction

A pharmaceutical company based in Mexico aimed to expand its dermatology portfolio by incorporating innovative topical therapies for underdiagnosed and underserved conditions. To achieve this, the company partnered with Trifermed to scout and evaluate novel treatments available for in-licensing and facilitate a strategic partnership with an international dermatology specialistorganization.

Through Trifermed’s structured approach to portfolio development and strategic partnerships, the company secured a licensing agreement for a EU-approved novel topical therapy designed to treat severe primary axillary hyperhidrosis., a chronic dermatological condition with significant unmet needs, particularly among adolescents.

Background

Severe primary axillary hyperhidrosis, characterized by excessive sweating in the underarm area, significantly impacts quality of life and social functioning, especially in younger patients. .While effective therapies exist, they are limited in accessibility and appropriate formulations for adolescent populations.and convenient formulations.

The primary objectives were:

  • Identifying  an innovative and clinically validated treatments with strong safety and efficacy data.

  • Structuring a licensing agreement for commercialization in Mexico.

  • Supporting strategic planning for regulatory approval and go-to-market execution.

Trifermed played a key role in identifying the opportunity and managing the end-to-end evaluation and negotiation process.

Services Provided

  • Portfolio Strategy & Asset Identification

  • Partner Identification & Evaluation

  • Deal Structuring & Negotiation Support

Outcomes & Future Development

As a result of this collaboration, the client secured exclusive rights to commercialize a novel topical treatment for severe primary axillary hyperhidrosis in Mexico, Peru and Colombia. The agreement enabled:

  • Therapeutic Innovation: Introduction of a non-invasive treatment option targeting adolescents with unmet medical needs.novel, targeted approach for managing severe primary axillary hyperhidrosis in adults with high efficacy, convenience and safety profile.

  • Portfolio Differentiation: Strengthening the company’s dermatology line with a first-in-class topical solution.

  • Regulatory Preparation: Establishing a roadmap for registration and successful launch.